New Drug Slashes Seizures in Children with Dravet Syndrome in Early Trial

A new drug, zorevunersen, is showing remarkable promise in early trials for treating children with Dravet syndrome, a rare and often devastating form of epilepsy. Initial results suggest the drug can slash seizure frequency by as much as 90%, and, crucially, appears to address the underlying genetic cause of the condition – a significant step beyond simply managing symptoms.

Dravet syndrome is a developmental and epileptic encephalopathy, meaning it’s a complex neurological condition that begins in infancy and leads to ongoing developmental challenges alongside difficult-to-control seizures. It’s estimated to affect around 1 in 15,700 children, and is frequently linked to mutations in the SCN1A gene. The Dravet Syndrome Foundation provides comprehensive information about the condition and its impact on families.

Tackling the Genetic Root

What sets zorevunersen apart is its approach. Unlike many existing epilepsy medications that focus on controlling seizures, this drug aims to correct the fundamental genetic defect driving Dravet syndrome. The SCN1A gene provides instructions for making a crucial component of nerve cells – sodium channels – which are essential for proper brain function. In many individuals with Dravet syndrome, a genetic alteration hinders the production of functional protein from one copy of the SCN1A gene. Zorevunersen works by boosting the output of the remaining, healthy copy of the gene, effectively compensating for the deficiency.

This mechanism utilizes a type of molecule called an antisense oligonucleotide. These molecules can increase the amount of messenger RNA – the molecule that carries genetic instructions – for the working version of the SCN1A protein. Live Science explains the potential of antisense oligonucleotides in treating a range of genetic diseases.

The drug is administered via a lumbar puncture – an injection into the spinal fluid – to ensure it reaches the brain. Even as this requires regular clinic visits, the study suggests the benefits can last for several months after each dose.

Early Trial Results and What They Mean

The findings, published in The New England Journal of Medicine on March 4th, reach from a Phase 1/2 clinical trial involving 81 children aged 2 to 18, conducted at hospitals in the U.K. And the U.S. The primary goal of this initial study was to assess the drug’s safety and determine the optimal dosage. Though, researchers also observed encouraging improvements in seizure reduction, neurodevelopmental progress, and overall quality of life, particularly at higher doses.

After 20 months of treatment, children receiving the highest dose experienced a 59% to 91% reduction in seizure frequency. Importantly, the trial also indicated that zorevunersen was generally well-tolerated, with most side effects being mild, such as headaches or vomiting related to the lumbar puncture procedure, or a temporary increase in protein levels in the cerebrospinal fluid.

Dravet syndrome presents a complex clinical picture. Beyond seizures, children with the condition often experience developmental delays, coordination difficulties, and behavioral challenges. Tragically, approximately half of those affected face a heightened risk of premature, sudden death. These symptoms stem from disruptions in the function of interneurons – specialized cells that play a vital role in regulating brain activity. While existing treatments like anti-epileptic drugs and implanted devices can help manage seizures, they don’t address the underlying developmental issues.

Understanding the Limitations and Next Steps

It’s crucial to emphasize that these are early-stage trial results. The study was relatively small, and importantly, it did not include a placebo group – meaning there was no comparison group receiving a dummy treatment. This makes it harder to definitively attribute the observed improvements solely to zorevunersen. Correlation does not equal causation, and further research is needed to confirm these findings.

A larger, Phase 3 clinical trial is already underway, enrolling an additional 170 children to compare the effects of zorevunersen against a control group. This will provide more robust evidence to determine whether the drug truly offers a significant benefit. The Epilepsy Foundation offers detailed information about Dravet syndrome and ongoing research efforts.

Even with positive results from the Phase 3 trial, it will likely be several years before zorevunersen becomes widely available to children with Dravet syndrome. The trial is expected to conclude in October 2028, and regulatory review and approval processes will follow.

What to expect in the coming years

Researchers are cautiously optimistic about the potential of zorevunersen to alter the course of Dravet syndrome. Dr. Helen Cross, the study leader and a professor of childhood epilepsy at University College London, emphasized that the drug is “targeting the actual underlying cause of the problem,” with the hope of not only reducing seizures but also improving other aspects of the disease. Dr. Cross’s profile at UCL provides further details about her research.

For families affected by Dravet syndrome, this research offers a glimmer of hope. While challenges remain, the development of zorevunersen represents a significant step forward in the search for effective treatments for this devastating condition. It’s important for families to stay informed about ongoing research and to discuss any questions or concerns with their child’s healthcare team.